Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3516-3522

  Flynn, Patricia M ^a,b   Rodman, John ^a   Lindsey, Jane C ^c   Robbins, Brian ^a   Capparelli, Edmund ^d   Knapp, Katherine M ^a,b   Rodriguez, Jose F ^e,f   McNamara, James ^g   Serchuck, Leslie ^h   Heckman, Barbara ⁱ   Martinez, Jaime ^j   Martinez, J ^k   Bojan, K ^k   Nesheim, S ^l   Dennis, R ^l   Kovacs, A ^m   Homans, J ^m   Knapp, K ^a   DiScenza, S ^a   Van Dyke, R B ⁿ   Sillio, V ⁿ   Palumbo, P ^o   Rodriguez, J F ^e   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^f Institute of Biomedical and Forensic Sciences Research of Puerto Rico Inc   (Puerto Rico)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^j Jr Hospital of Cook County   (United States)

^k and Research of Infectious Disease   (United States)

^l EMORY UNIVERSITY HOSPITAL   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^o UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DRUG METABOLITE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; CHILD; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HUMANS; LAMIVUDINE; MALE; MONOCYTES; PHOSPHORYLATION; ZIDOVUDINE;

EID: 34948835670     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01626-06     Document Type: Article

References (28)

1. Anderson, P. L., T. N. Kakuda, S. Kawle, and C. V. Fletcher. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168.
2. Barry, M. G., S. H. Khoo, G. J. Veal, P. G. Hoggard, S. E. Gibbons, E. G. Wilkins, O. Williams, A. M. Breckenridge, and D. J. Back. 1996. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10:1361-1367.
3. Bilello, J. A., J. L. Eiseman, H. C. Standiford, and G. L. Drusano. 1994. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob. Agents Chemother. 38:628-631.
4. Blum, M. R., S. H. Liao, S. S. Good, and P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85:89-94.
5. Collier, A. C., S. Bozzette, R. W. Coombs, D. M. Causey, D. A. Schoenfeld, S. A. Spector, C. B. Pettinelli, G. Davies, D. D. Richman, and J. M. Leedom. 1990. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N. Engl. J. Med. 323:1015-1021.
6. Drusano, G. L., P. A. Bilello, W. T. Symonds, D. S. Stein, J. McDoweell, A. Bye, and J. A. Bilello. 2002. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob. Agents Chemother. 46:464-470.
7. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, and M. Rubin. 1995. Treatment with lamivudine, zidovudine or both in HIV-positive subjects. N. Engl. J. Med. 333:1662-1669.
8. Fletcher, C. V., E. P. Acosta, K. Henry, L. M. Page, C. R. Gross, S. P. Kawle, R. P. Remmel, A. Erice, and H. H. Balfour, Jr. 1998. Concentration-controlled zidovudine therapy. Clin. Pharm. Ther. 64:331-338.
9. Flynn, P. M., B. J. Rudy, S. D. Douglas, J. Lathey, S. A. Spector, J. Martinez, M. Silio, M. Beizer, L. Friedman, L. D'Angelo, J. McNamara, J. Hodge, M. D. Hughes, J. C. Lindsey, et al. 2004. Virologic and immunologic outcomes after 24 weeks in HIV-1-infected adolescents on highly active antiretroviral therapy. J. Infect. Dis. 190:271-279.
10. Hahn, G. J., and W. Q. Meeker. 1991. Statistical intervals: a guide for practitioners. John Wiley & Sons, Inc., New York, NY.
11. Johnson, M. A., K. H. P. Moore, G. J. Yuen, A. Bye, and G. E. Pakes. 1999. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:41-66.
12. Laskin, O. L., P. de Miranda, and M. R. Blum. 1989. Azidothymidine steady-state pharmacokinetics in subjects with AIDS and AIDS-related complex. J. Infect. Dis. 159:745-747.
13. McKinney, R. E., Jr., G. M. Johnson, K. Stanley, F. H. Yong, A. Keller, K. J. O'Donnell, P. Brouwers, W. G. Mitchell, R. Yogev, D. W. Wara, A. Wiznia, L. Mofenson, J. McNamara, and S. A. Spector. 1998. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children. J. Pediatr. 133:500-506.
14. Moore, K. H., J. E. Barrett, S. Shaw, G. E. Pakes, R. Churchus, A. Kapoor, J. Lloyd, M. G. Barry, and D. Back. 1999. The pharmacokinetics of lamivudine triphosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13:2239-2250.
15. Peter, K., and J. G. Gambertoglio. 1998. Intracellular phosphorylation of zidovudine and other nucleoside reverse transcriptase inhibitors for HIV infection. Pharm. Res. 75:819-825.
16. Richman, D. 1991. Antiviral therapy of HIV infection. Annu. Rev. Med. 42:69-90.
17. Robbins, B. L., T. T. Tran, F. H. Pinkerton, Jr., F. Akeb, R. Guedj, J. Grassi, D. Lancaster, and A. Fridland. 1998. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 42:2656-2660.
18. Robbins, B. L., B. H. Waibel, and A. Fridland. 1996. Quantitation of intracellular zidovudine phosphates by use of combined cartridge- radioimmunoassay methodology. Antimicrob. Agents Chemother. 40:2651-2654.
19. Rodman, J. H., P. M. Flynn, B. Robbins, E. Jimenez, A. D. Bardeguez, J. F. Rodriguez, S. Blanchard, and A. Fridland. 1999. Systemic pharmacokinetics and cellular pharmacology of in human immunodeficiency virus type-1-infected women and newborn infants. J. Infect. Dis. 180:1844-1850.
20. Rodman, J. H., B. Robbins, P. M. Flynn, and A. Fridland. 1996. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in subjects. J. Infect. Dis. 74:490-499.
21. Rodriguez, J. F., J. L. Rodriguez, J. Santana, H. Garcia, and O. Rosario. 2000. Simultaneous quantitations of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob. Agent Chemother. 44:3097-3100.
22. Ruane, P. J., G. J. Richmond, E. DeJesus, C. E. Hill-Zabala, S. C. Danehower, Q. Liao, J. Johnson, M. S. Shaefer, et al. 2004. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naive patients infected with human immunodeficiency virus. Pharmacotherapy 24:307-312.
23. Shepp, D. H., C. Ramirez-Ronda, L. Dall, R. B. Pollard, R. L. Murphy, H. Kessler, R. Sherer, G. Mertz, G. Perez, D. J. Gocke, S. B. Greenberg, E. Petersen, I. Frank, M. D. Moore, R. McKinnis, and J. F. Rooney. 1997. A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15:283-288.
24. Smiley, L. 1989. Zidovudine treatment of subjects with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: long-term experience. J. Infect. 18(Suppl. 1):77.
25. Volberding, P. A., S. W. Lagakos, J. M. Grimes, D. S. Stein, H. H. Balfour, Jr., R. C. Reichman, J. A. Bartlett, M. S. Hirsch, J. P. Phair, R. T. Mitsuyasu, et al. 1994. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 272:437-442.
26. Volberding, P. A., S. W. Lagakos, J. M. Grimes, D. S. Stein, J. Rooney, T. C. Meng, M. A. Fischl, A. C. Collier, J. P. Phair, M. S. Hirsch, et al. 1995. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N. Engl. J. Med. 333:401-407.
27. Volberding, P. A., S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, H. H. Balfour, Jr., R. C. Reichman, J. A. Bartlett, M. S. Hirsch, et al. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl. J. Med. 322:941-949.
28. Yuen, G. J., Y. Lou, N. F. Bumgarner, J. P. Bishop, G. A. Smith, V. R. Otto, and D. D. Hoelscher. 2004. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob. Agents Chemother. 48:176-182.